Workflow
RBC Capital Reiterates a Buy Rating on Legend Biotech Corporation (LEGN)

Legend Biotech Corporation (NASDAQ:LEGN) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 12, Leonid Timashev from RBC Capital reiterated a Buy rating on Legend Biotech Corporation (NASDAQ:LEGN) and set a price target of 77.00.LegendBiotechCorporation(LEGN):AmongTakeoverRumorsHedgeFundsAreBuyingLegendBiotechCorporation(NASDAQ:LEGN)reportedCARVYKTInettradesalesofaround77.00. Legend Biotech Corporation (LEGN): Among Takeover Rumors Hedge Funds Are Buying Legend Biotech Corporation (NASDAQ:LEGN) reported CARVYKTI net trade sales of around 439 million in fiscal Q2 2025, with CARVYKTI demonstr ...